Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM1A | O60341 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16640301 | 0.99 | MALT1 (0.67) | MALT1PTGS2CHRNA7MEN1KMT2A | |
| SCHEMBL16640298 | 0.87 | MALT1 (0.57) | MALT1PTGS2CHRNA7MEN1KMT2A | |
| SCHEMBL15004248 | 0.87 | MALT1 (0.57) | MALT1PTGS2CHRNA7MEN1KMT2A | |
| SCHEMBL16640299 | 0.85 | MALT1 (0.58) | MALT1PTGS2CHRNA7MEN1KMT2A | |
| SCHEMBL9201596 | 0.83 | MALT1 (0.65) | MALT1PTGS2CHRNA7MEN1KMT2A | |
| SCHEMBL9201626 | 0.82 | PTGS2 (0.67) | MALT1PTGS2CHRNA7PTGS1 | |
| SCHEMBL18353048 | 0.81 | PTGS2 (0.51) | MALT1PTGS2CHRNA7MEN1KMT2A | |
| SCHEMBL18358765 | 0.80 | PTGS2 (0.50) | MALT1PTGS2MEN1KMT2AMAPT | |
| SCHEMBL15004253 | 0.80 | PTGS2 (0.66) | MALT1PTGS2CHRNA7KDM1AATM | |
| SCHEMBL18353060 | 0.77 | KDM1A (0.49) | MALT1PTGS2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105388-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105388-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105388-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | PAICS, AADAC, TPMT | MALT1 28/4885PTGS2 3350/4885CHRNA7 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.